Skip to content

Evaluation of the Abbott i-STAT TBI Biomarker Test

Evaluation of the Abbott i-STAT TBI Biomarker Test for Effect on Decreasing CT Utilization Among Adult Emergency Department Patients With Suspected Traumatic Brain Injury

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06766435
Enrollment
450
Registered
2025-01-09
Start date
2025-01-30
Completion date
2025-10-31
Last updated
2025-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury

Keywords

Point of Care Testing, Emergency Care, Clinical Decision Making, Head Injury

Brief summary

According to the Centers for Disease Control and Prevention, approximately 200,000 hospitalizations occurred in 2020 related to Traumatic Brain Injury (TBI), which does not include many TBIs treated only in emergency departments, urgent care, primary care, or that are not evaluated by a clinician. Head CT is a critical component of care for severe TBI, however in mild TBI there is practice variation with a wider risk to benefit estimation for obtaining head CT imaging. Potential disadvantages of head CT include longer Emergency Department (ED) length of stay (LOS), higher costs, and diagnostic radiation exposure. The i-STAT TBI test is a panel of in vitro diagnostic immunoassays for the quantitative measurements of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in whole blood and a semi-quantitative interpretation of test results derived from these measurements, using the i-STAT Alinity instrument. This biomarker test is cleared for use in adults with mild TBI (Glasgow Coma Scale 13-15) within 24 hours of injury, to aid in determining the need for head CT imaging. Currently, CT head imaging for adults with suspected mild TBI is obtained based on clinicians' usual practice patterns and beliefs about patient expectations. Prior research has demonstrated the blood TBI test may reduce unnecessary CT scans by up to 40%, however the impact on head CT ordering has not yet been studied prospectively. It is important to understand the extent to which a negative TBI biomarker result empowers a clinician to cancel a previously ordered head CT. Given that adult patients with mild TBI often present to EDs, which have access to CT scanners, this is a key setting to assess real-world impact of the i-STAT TBI test on CT head utilization.

Interventions

DEVICEi-STAT TBI Test

The Abbott i-STAT TBI test result is shared with the enrolled patient and treating clinicians.

Sponsors

Abbott Point of Care
CollaboratorINDUSTRY
Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

Patient is randomized to the intervention or control arm after consent is obtained. There is no masking for the treatment arm assignment. In the non-notification arm (control arm) participants and care providers will not learn the results of the i-STAT TBI test.

Intervention model description

Multisite randomized controlled clinical trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Head injury within 24 hours of research blood collection * CT head ordered as part of routine care, not yet completed. * Glasgow Coma Scale (GCS) 13 - 15

Exclusion criteria

* Unknown whether head injury occurred, and signs of head injury are absent * Previously enrolled in this study in the past 30 days * Prisoner or in police custody or known pregnancy * Suspected current ischemic or hemorrhagic stroke * Suspected open or depressed skull fracture, or signs of skull base fracture * History of multiple sclerosis * Venipuncture not feasible

Design outcomes

Primary

MeasureTime frameDescription
Number of Head CT scans canceledWithin 24 hours of Traumatic Brain InjuryNumber of head CTs canceled in patients not on anticoagulants as measurement of percentage of reduction in the number of canceled head CTs out of total head CTs ordered (total number and percentage)

Secondary

MeasureTime frameDescription
ED Length of StayDay 1 after patient ED care visit has endedLength of stay for the Emergency Department patient encounter
Number of cancellations of head CT scan order in patients on anticoagulantsDay 1 after patient ED care visit has endedNumber of cancellations in head CTs in patients on anticoagulation
Patient Satisfaction ScaleAt 14 days after ED visitAssessment of patient satisfaction with care during ED visit. Full scale from 1 (worst care possible) to 10 (best care possible)
Number of head CT scans completedAt 14 days after ED visitNumber of head CT scans completed for patients within 14 days after index ED visit
Subset of Number of Head CT scans completedWithin 24 hours of Traumatic Brain InjuryIf the i-STAT TBI test results had been strictly adhered to by clinicians, subset of negative i-STAT TBI test results, Potential reduction in the number of completed head CTs (canceled) out of total head CTs ordered (total number and percentage)
Malpractice Fear Scale (MFS) ScoresDay 1 during patient ED care visitMalpractice Fear Scale (MFS) scores. MFS scores range from 6 to 36 with a higher score indicating greater fear of malpractice.
Whole blood concentrations of GFAP (glial fibrillary acidic protein)Day 1 during patient ED care visitWhole blood concentrations for GFAP on the iSTAT device. Biomarker for use with mild TBI within 24 hours of injury to aid in determining the need for head CT imaging.
Whole blood concentrations of UCH-L1 (ubiquitin C-terminal hydrolase L1)Day 1 during patient ED care visitWhole blood concentrations for UCH-L1 on the iSTAT device. Biomarker for use with mild TBI within 24 hours of injury to aid in determining the need for head CT imaging.
Stress of Uncertainty Scale (SUS)Day 1 during patient ED care visitClinicians vary in their use of diagnostic testing and treatments, and stress of uncertainty may be one explanation for this variation. The stress of uncertainty scale measures clinician tolerance of uncertainty during patient care. SUS scores range from 15-90 with a higher score indicating greater fear of uncertainty.

Countries

United States

Contacts

Primary ContactMitali Pradhan, MS, CCRP
Mitali.Pradhan@mountsinai.org201-423-3585
Backup ContactJonathan Schimmel, MD
jonathan.schimmel@mountsinai.org

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026